Sign in Subscribe

targeted-therapy

A collection of 104 issues

Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC A matching-adjusted indirect comparison evaluated sotorasib plus panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice.

KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic

Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer

Skip to content The CRC Digest ▸ TREATMENT Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer A patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer responded to re-challenge with encorafenib and cetuximab combined with nivolumab after prior progression, suggesting this combination may offer renewed

Phase 2 study evaluates pembrolizumab combination for MSS/pMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 study evaluates pembrolizumab combination for MSS/pMMR metastatic colorectal cancer A Phase II study tested pembrolizumab plus capecitabine and bevacizumab in microsatellite stable/mismatch repair-proficient metastatic colorectal cancer, a population that typically does not respond well to immunotherapy alone. (Clinical

Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC A study across 10 Japanese hospitals aimed to evaluate trifluridine/tipiracil (with or without bevacizumab) in MSI-H/dMMR metastatic colorectal cancer, a population known to resist standard fluorouracil-based therapies. (Therapeutic Advances in Medical Oncology)

ALK Fusions Identified as Rare but Targetable Drivers in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH ALK Fusions Identified as Rare but Targetable Drivers in Colorectal Cancer Comprehensive genomic profiling of 56,206 advanced colorectal tumors characterized the prevalence and therapeutic implications of ALK fusions, which are established targets in lung cancer but rare in CRC. (The Oncologist) This

Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease

Skip to content The CRC Digest Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease A comprehensive review discusses how ctDNA and immune biomarkers such as mismatch repair deficiency, microsatellite instability, and tumor mutational burden can identify patients at high risk of recurrence and guide adjuvant

Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases

Skip to content The CRC Digest ▸ TREATMENT Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients

HER2-mutated colorectal cancers show distinct genomic features from HER2-amplified tumors

Skip to content The CRC Digest ◇ RESEARCH HER2-mutated colorectal cancers show distinct genomic features from HER2-amplified tumors Analysis of 4,348 CRC patients found that ERBB2/HER2 mutations occurred in 2.2% and amplifications in 2.0%, with distinct genomic landscapes and clinical characteristics between the two groups. (Oncologist) This

First Patient Dosed in Phase 2 Trial of Oral KRAS G12D Inhibitor

Skip to content The CRC Digest ▸ TREATMENT First Patient Dosed in Phase 2 Trial of Oral KRAS G12D Inhibitor Verastem Oncology has dosed the first patient in a phase 2 registration-directed trial of VS-7375, an oral KRAS G12D inhibitor, for KRAS G12D-mutated metastatic colorectal cancer. (BioSpace) This content is informational